ASCENTAGE PHARMA GROUP INTERNATIONAL (“ASCENTAGE-B”) has released a supplemental notice for its 2026 Annual General Meeting (AGM), scheduled for 10:00 a.m. on 20 May 2026 at 68 Xinqing Road, Suzhou Industrial Park, Jiangsu, China. While resolutions Nos. 1–8 remain unchanged from the 28 April 2026 notice, two additional ordinary resolutions will now be tabled:

1. Approval of Restricted Share Units (RSUs) for Chairman and Executive Director Dr. Yang Dajun and Dr. Zhai under the 2022 RSU Scheme. 2. Approval of share options for the same executives under the Post-IPO Share Option Scheme.

To accommodate the expanded agenda, the company has issued a Second Proxy Form, which replaces the form circulated with the original notice. Shareholders must submit the new form to Tricor Investor Services Limited—or complete it online—no later than 10:00 a.m. on 18 May 2026 if they wish to appoint a proxy.

Failure to lodge the Second Proxy Form leaves the First Proxy Form valid; however, submitting the Second Proxy Form before the deadline will automatically revoke any earlier proxy instructions.

Board composition remains unchanged, comprising Dr. Yang Dajun (Chairman and Executive Director), two non-executive directors, and seven independent non-executive directors. No other modifications to the AGM notice or meeting logistics have been announced.